Voyager Therapeutics Files 8-K
Ticker: VYGR · Form: 8-K · Filed: May 6, 2025 · CIK: 1640266
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: VYGR
TL;DR
Voyager Therapeutics (VYGR) filed an 8-K on 5/6/25 updating its corporate address in Lexington, MA.
AI Summary
On May 6, 2025, Voyager Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 75 Hayden Avenue, Lexington, Massachusetts, 02421. Voyager Therapeutics, Inc. is incorporated in Delaware and operates in the Biological Products sector.
Why It Matters
This 8-K filing provides updated corporate information and addresses for Voyager Therapeutics, Inc., which is important for investors and stakeholders to have the most current contact and operational details.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain material financial or operational news that would typically impact risk.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- May 6, 2025 (date) — Date of Report
- 75 Hayden Avenue Lexington, Massachusetts 02421 (location) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report current information as required by the Securities Exchange Act of 1934, specifically detailing the company's principal executive offices and other corporate information.
When was this 8-K report filed?
This 8-K report was filed on May 6, 2025.
Where are Voyager Therapeutics, Inc.'s principal executive offices located?
Voyager Therapeutics, Inc.'s principal executive offices are located at 75 Hayden Avenue, Lexington, Massachusetts, 02421.
In which state is Voyager Therapeutics, Inc. incorporated?
Voyager Therapeutics, Inc. is incorporated in Delaware.
What is Voyager Therapeutics, Inc.'s Standard Industrial Classification (SIC) code?
Voyager Therapeutics, Inc.'s Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 6, 2025 regarding Voyager Therapeutics, Inc. (VYGR).